Albany, NY -- (SBWIRE) -- 09/02/2016 -- The increasing prevalence of various psychological problems such as stress and sleeplessness is boosting the demand for MDD, anxiety, and panic disorder therapeutics. In its report, titled "MDD, Anxiety and Panic Disorder Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020," Transparency Market Research (TMR) studies the various factors impacting the market's trajectory.

Recent patent expiries did create a few bottlenecks for the market, but key players are investing in the research and development to discover novel therapeutics. Presently, cognitive-behavioral therapy (CBT) is an effective treatment for psychological disorder but it requires the support of anti-depressants in the first line of treatment, apart from other drugs. However, administering anti-depressants could trigger panic attacks in patients with bipolar disorders, which can be analyzed by mapping the patient's family history before diagnosis.

Lack of awareness about comparable theories could prove damaging for the market. Hence, the leading producers of MDD, anxiety, and panic disorder therapeutics have been finding it difficult to penetrate underdeveloped regions as they lack adequate support of skilled medical professionals. Nevertheless, opportunities across developing and underdeveloped economies are expected to rise as their governments plan to accelerate healthcare spending.

Based on recent updates, TMR forecasts promising growth for the global MDD, anxiety, and panic disorder market. The forthcoming patent expiry of blockbuster drugs such as Eli Lilly's Cymbalta and BMS/Otsuka's Abilify is likely to create growth opportunities for market players. Besides this, the key market players are also looking to gain from pipeline products such as Alkermes and Forest (Actavis)/Gedeon's ALKS-5461, Naurex's GLYX-13, and Richter/Mitsubishi Tanabe Pharma's cariprazine. Approval of these pipeline drugs will fuel sales prospects in the market.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2928

Epidemiologic studies have found that a majority of individuals experiencing panic attacks are likely to experience MDD at some point. This factor boosts the chances of the co-occurrence of panic disorders. These disorders can lead to functional disability along with triggering suicidal instincts in patients. Be it the current hectic lifestyle or a prolonged family history of anxiety, the world today is witnessing more cases of MDD, anxiety, and panic disorders than ever before. This would accelerate the demand for effective diagnosis and treatment modalities to help patients not succumb to the condition.

TMR therefore forecasts that the demand for novel therapeutics will surge in response to the rising incidence of anxiety, panic disorders, and MDD. Some of the key players in the global MDD, anxiety, and panic disorder market likely to gain from the prevailing trends are Forest Laboratories, Shire Plc, Astra Zeneca Plc, Novartis AG, Eli Lilly and Company, BTG International (BTG), Janssen Pharmaceuticals, Inc. (JPI), Pfizer, Inc., H. Lundbeck A/S, and Alexza Pharmaceuticals.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: 518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/